Breast Cancer: Biology, Risk, PreventionCME Physicians - up to 1.5 hours of AMA PRA category 1 credit; Pharmacists - up to 1.5 contact hours (0.15 CEUs); Registered Nurses - up to 1.8 Nursing Continuing Education contact hours Breast Cancer Genetics: The Decade in Review Robert Mocharnuk, MD Advances in Basic Science -- Will They Translate to Better Therapies? Kathy D. Miller, MD Ductal Carcinoma In Situ: What Do We Know Now? Harold J. Burstein, MD PhD More...
Breast Cancer Therapy 2002CME Physicians - up to 1.5 hours of AMA PRA category 1 credit; Pharmacists - up to 1.5 contact hours (0.15 CEUs); Registered Nurses - up to 1.8 Nursing Continuing Education contact hours Taxanes in Breast Cancer: From Neoadjuvant Therapy to Treatment of Metastatic Disease Joseph A. Sparano, MD Adjuvant Chemotherapy Overview: Old Drugs, New Tricks Clifford A. Hudis, MD Treatment of Metastatic Breast Cancer George W. Sledge, Jr, MD More...
Breast Cancer Therapy: New DirectionsCME Physicians - up to 1.0 hours of AMA PRA category 1 credit; Pharmacists - up to 1.0 contact hours (0.10 CEUs); Registered Nurses - up to 1.2 Nursing Continuing Education contact hours New Prognostic and Predictive Factors: Are They Ready for Clinical Use? Kathleen I. Pritchard, MD, FRCPC Aromatase Inhibitors: The State of the Art Kathleen I. Pritchard, MD, FRCPC Update on Adjuvant Endocrine Therapy: Focus on Anastrozole, Tamoxifen, and Goserelin Nicholas J. Robert, MD More...
Celecoxib May Improve Breast Cancer Outcomes 12/16/02 [Medscape Medical News] In a pilot study, this drug improved response compared with that of chemotherapy alone, suggesting that it may allow more breast-conserving procedures.
Mastectomy More Common in US Than in UK 12/13/02 [Medscape Medical News] Physician bias may play a role in the high rate of mastectomy compared with lumpectomy.
New Treatment Options in Advanced Breast Cancer 12/11/02 [Medscape Medical News] Anastrozole with tamoxifen or fulvestrant may be effective in patients refractory to conventional chemotherapy.
Legal Disclaimer
The materials presented here were prepared by independent authors under the editorial supervision of Medscape, and do not represent a publication of the San Antonio Breast Cancer Symposium. These materials and the related activity are not sanctioned by the San Antonio Breast Cancer Symposium or the commercial supporter of the conference, and do not constitute an official part of that conference.
The material presented here does not reflect the views of Medical Education Collaborative, Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing medical education activity.
Breast Cancer Genetics: The Decade in Review